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Epidemiological methods are essential for the discovery of cancer risks and prognostic factors as well as for the
evaluation of cancer prevention measures. In this review, we discuss epidemiological surveillance procedures for
data collection and processing to guide and evaluate the consequences of anticancer efforts for populations,
assess the identification of cancer risk factors, examine barriers to cancer screening and recommended rules for
early diagnosis programs. Epidemiological studies have shown that hindrances to cancer information assess-
ment are currently encountered in developing countries. Known cancer risk factors include social determinants,
lifestyle factors, occupational exposures, infectious agents, and genetic and epigenetic alterations. Challenges
remain in studying the effectiveness of cancer screening; screening can have detrimental effects, and few cancers
clearly benefit from screening. Currently, epidemiology faces the challenge of dealing with distinct levels of
data, including factors related to social status, lifestyle and genetics, to reconstruct the causal traits of cancer.
Additionally, translating epidemiological knowledge into cancer control demands more implementation studies
in the population.
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’ INTRODUCTION
Epidemiology provides information on the distribution of
cancer in a population and on cancer determinants and then
applies this knowledge to disease control (1). Cancer surveil-
lance, a key attribute of epidemiology and public health
practice, provides intelligence data on the burden of different
types of cancer in a specified population and, through evidence-
based health programs, assesses the success of actions against
cancer. Features related to other health outcomes in cancer
patients, such as survival after diagnosis and treatment, also
fall within the scope of epidemiology and may help define
criteria for a strategy against cancer (2). Information regarding
diagnosis, treatment and palliative care is widely assessed via
clinical epidemiology studies, systematic review methods and
meta-analysis models and is required to support evidence-
based protocols and design approaches to satisfy clinical
priority criteria.
Half of all patients who develop cancer can be cured by
currently available treatment resources, but the other half
will die from the disease (3). According to the World Health
Organization (WHO), approximately 40% of all cancer cases
are preventable (4), and considering the global cancer load
and the vast resources needed for disease management,
public responses have been proposed in many countries.
A comprehensive national cancer control plan was designed in
the US in the 1990s to minimize the repercussions of cancer
on the American population (5). In 2005, the 58th World
Health Assembly published a resolution calling on member
states to intensify efforts against cancer through control
programs (2). Afterwards, the WHO published a guide for
cancer control programs (4) that provided practical advice
for program managers and policy makers on how to advo-
cate, plan and implement cancer control programs, parti-
cularly in low- and middle-income countries. Four basic
components were emphasized—prevention, early detec-
tion, treatment and palliative care—and evidence-based
programs for planning and monitoring cancer control were
established.
In this article, we discuss surveillance procedures regard-
ing data collection and processing for evaluating the impact
of both cancer and anticancer efforts on populations. We also
discuss aspects related to the identification of cancer risk
factors, which is a main mission of epidemiology, and exam-
ine some cancer screening barriers and recommended rules
for early diagnosis programs.
Assessment of cancer burden
Cancer is a global disease with many disparities among
regions, countries and even geographical areas within coun-
tries. Several measures are used to estimate cancer burden,
including incidence, prevalence, mortality, survival, years of
life lost (YLL), years lived with disability (YLD) and disability-
adjusted life years (DALY). Cancer surveillance includes
systematically measuring cancer parameters, recording and
transmitting data, and comparing and interpreting data to
detect changes in cancer status in a population (6). Cancer
surveillance is based on data from both vital statistics, parti-
cularly mortality, and risk factor prevalence surveys.DOI: 10.6061/clinics/2018/e627s
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Cancer registries are important tools for planning and
monitoring efforts at all prevention levels (7). Epidemio-
logists have played a key part in the development and
improvement of cancer registries, which began in the US and
Germany in the 1920s and currently exist worldwide.
Hospital-based cancer registries record data from cases
in specific hospitals and provide information about patients
and treatment, aiming to contribute to patient care. These
registries do not supply cancer incidence rate statistics but
are relevant for appraising other variables, such as cancer
patient survival. Population-based cancer registries distinctly
emphasize public health demands; these registries collect
data on cancer occurrences in delimited populations and
furnish valuable information for epidemiological studies and
for identifying intervention priorities, especially in resource-
limited locations (6).
Reports on global cancer incidence, mortality and pre-
valence rates are produced periodically by the International
Agency for Research on Cancer (IARC). The publication
Cancer Incidence in Five Continents (CI5) includes cancer
rates from population-based cancer registries worldwide.
Almost 100% of the North American population is included
in the CI5, whereas less than 10% of the Latin American,
Caribbean, Asian and African populations are covered (8).
Furthermore, the IARC produces estimates of global cancer
statistics through the Globocan project, an interactive web-
based platform whose latest version was created in 2012 (9).
In the 1990s, the Global Burden of Disease (GBD) Study
initiative began, aiming to use the expertise of epidemio-
logists and other professionals to quantify the comparative
magnitudes of health loss over time from diseases, injuries,
and risks by age, sex, and population. Currently, the GBD
study covers 195 countries and territories and assesses 333
diseases and injuries, 2982 sequelae of these diseases and
injuries, and 84 risks or combinations of risks. The GBD
study provides information for decision makers at local,
regional, national, and global levels (10-12).
Cancer is the second leading cause of death worldwide,
causing 8.8 million deaths in 2015. Globally, the incidence
of cancer rose to 18.6 million in 2015, and the prevalence, or
the number of people living with cancer, was approximately
90.5 million (10,11). More than 60% of cancer cases and approxi-
mately 70% of cancer deaths occur in low- and middle-
income countries. As a consequence of population aging,
the worldwide new cancer cases increased by 33%
from 2005 to 2015 (13). In this same period, the number
of deaths from cancer increased by 17.0%, while the age-
standardized death rate decreased by 10% (11). The age-
standardized death rate for all cancers decreased in 72% of
the countries assessed by the GBD; increasing trends were
observed primarily in African countries (13). Between 2005
and 2015, esophageal cancer (-26.8%) and Hodgkin’s lym-
phoma (-23.9%) exhibited the largest reductions in age-
standardized death rates, while the death rates due to
non-melanoma skin cancer (7.6%) and mesothelioma (7.8%)
increased (11).
Figure 1 was created using data from the GBD and shows
trends in estimated cancer-specific mortalities according to
income both worldwide and in Brazil from 1990 to 2016.
Disparities are obvious, with pronounced decreasing trends
for lung and stomach cancer in men and for colorectal cancer
in women in countries with a high or high-middle socio-
demographic index (SDI). The SDI is based on the average of
the per capita income, average educational attainment, and
fertility rates of all areas in the GBD study and is measured
on a scale of 0 to 1 (11). The values for cervical cancer, which
is very preventable, are much higher in low-SDI countries.
Differences in cancer burden according to time or geo-
graphical region may generate hypotheses regarding causes
of cancer for testing in individual studies. For example,
Garland and Garland (14) conducted an ecological study on
the correlation between colorectal cancer mortality rates and
solar radiation in the US. An inverse correlation, possibly
attributable to vitamin D levels, was found. In addition, the
potential protective effects of sun exposure and vitamin D
levels on other cancer sites was examined (15,16). Further
case-control and cohort studies were conducted, and vitamin D
and cancer had a consistent inverse causal relationship only
for colorectal cancer; however, these results were not con-
firmed in randomized clinical trials (17). The results of clinical
trials assessing the effectiveness of vitamin D supplementa-
tion in preventing colorectal adenoma occurrence and recur-
rence have been inconsistent (18,19). Therefore, knowledge
gaps are evident, and more studies testing this hypothesis
are necessary.
Causes of cancer
In a comprehensive study conducted in 1981 encompass-
ing the entire US population in 1978, Doll and Peto (20)
attempted to estimate the influence of different cancer causes
in a population for the first time. They estimated that approxi-
mately 30% of all cancer deaths in the US (43% in men and
15% in women) were due to tobacco smoking. Furthermore,
they estimated a similar impact for diet and nutrition and
attributed 4% of cancer deaths to carcinogen exposure in
the workplace and approximately 10% to infections. The
estimates from that study have not changed substantially,
even after nearly 40 years (21). Although the percentage of
cancer attributable to infectious agents increased to 15.4%
worldwide, this increase was not uniform; the percentage
was 23.4% in low- and middle-income countries but only
9.2% in more developed countries (22).
Public health measures for controlling both cancer inci-
dence and mortality are feasible since a relatively high pro-
portion of cancer cases may be explained by known risk
factors. Approximately 43% of cancer cases in the UK (23)
in 2010 were attributable to 12 lifestyle and environ-
mental factors. Estimates for the Brazilian population show
that approximately 35% of all cancer cases and between
39% (women) and 46% (men) of deaths will be attribu-
table to known lifestyle and environmental risk factors in
2020 (24).
The multifactorial etiology of cancer is an arduous chal-
lenge for epidemiologists, considering the complexity of
clearly determining human exposure to the factors involved
and assessing the interaction of these factors during carcino-
genesis. Epidemiological procedures for scrutinizing cancer
causes include different types of studies based on sophisti-
cated analysis techniques.
As cancer is a disease with a long period of susceptibility,
several strategies have been developed to investigate its
causes. The first case-control study on cancer was performed
by Janet Elizabeth Lane-Claypon, who collected data via a
questionnaire given to 500 hospitalized patients with breast
cancer and to an equal number of controls (25). Using simple
data presentation and standard statistical procedures, she
studied the effect of reproductive experiences in breast cancer
etiology (25,26). In 1959, after many case-control studies had been
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performed on the causes of cancer, Mantel and Haenszel (27)
developed statistical methods for risk estimation in retro-
spective studies; these methods are still in use today.
The first retrospective cohort studywas conducted by Bradford
Hill in an investigation of workers employed between 1929
and 1938 at a Welsh nickel refinery (28). Hill found that
Figure 1 - Age-standardized cancer-specific mortality rates in men and women. Source: Global Burden of Disease.
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16 deaths from lung cancer occurred although only one
was expected and that 11 deaths from nasal cancer occur-
red although fewer than one was expected. Currently,
evidence from new and more robust studies confirms the
role of nickel in lung cancer (29).
The IARC continuously publishes monographs on human
carcinogens after reviewing scientific evidence of the causal
contributions of chemicals, complex mixtures (e.g., air pollu-
tion), occupational exposures, physical and biological agents,
and personal habits. For an agent to be considered a human
carcinogen, evidence from epidemiological studies and from
study models in vivo and in vitro is needed (29,30). The IARC
classifies agents under review into four groups according
to the evidence for carcinogenicity: carcinogenic to humans
(group 1), probably carcinogenic to humans (group 2A),
possibly carcinogenic to humans (group 2B), not classifiable
as being carcinogenic to humans (group 3), or probably not
carcinogenic to humans (group 4) (29). By October 2017, the
IARC had classified 120 agents in group 1, 81 in group 2A,
and 299 in group 2B. In addition, the IARC publishes the
IARC Handbooks of Cancer Prevention, which provide scienti-
fic evidence related to reducing the cancer burden (31).
Table 1 provides information on factors currently classified
as group 1 human carcinogens by the IARC, as well as
primary prevention targets to reduce cancer occurrence, as
provided in the IARC Handbooks for Cancer Prevention,
and the organs affected (adapted from http://monographs.
iarc.fr/ENG/Publications/OrganSitePoster.pdf) (32).
Social determinants. Global inequalities in cancer bur-
den are patent, with disproportionately high incidences of
lifestyle-related cancers in countries classified as having a
Table 1 - Risk and preventive factors classified as carcinogenic/anticarcinogenic in epidemiological studies and the subsites affected.
Risk factor Sites affected
Lifestyle factors
Absence of excess body fat Thyroid, gastric cardia, liver (hepatocellular carcinoma), esophagus, gall bladder, colon and rectum,
pancreas, corpus uteri (endometrium), ovary, brain and central nervous system, kidney, multiple myeloma
Aflatoxins Liver (hepatocellular carcinoma)
Alcoholic beverages Oral cavity, pharynx, upper aerodigestive tract (acetaldehyde), liver (hepatocellular carcinoma), esophagus,
colon and rectum, larynx
Betel quid with tobacco Oral cavity, pharynx, esophagus
Betel quid without tobacco Oral cavity, esophagus
Processed meat Colon and rectum
Smoking cessation (preventive) Oral cavity, pharynx, stomach, esophagus, pancreas, uterine cervix, larynx, lung, kidney, urinary bladder
Regular physical activity Colon and rectum
Salted fish, Chinese-style Nasopharynx
Smokeless tobacco Oral cavity, esophagus, pancreas
Tobacco smoke, secondhand Lung
Tobacco smoking Oral cavity, pharynx, stomach, liver (hepatocellular carcinoma), esophagus, colon and rectum, pancreas,
uterine cervix, ovary, nasal cavity and paranasal sinus, larynx, lung, kidney, renal pelvis and ureter, urinary
bladder, leukemia/lymphoma
Infectious agents
Clonorchis sinensis Biliary tract
Epstein-Barr virus Nasopharynx, leukemia/lymphoma
Epstein-Barr virus Leukemia/ lymphoma
Helicobacter pylori Stomach, leukemia/lymphoma
Hepatitis B virus Liver (hepatocellular carcinoma)
Hepatitis C virus Liver (hepatocellular carcinoma), leukemia/lymphoma
Human immunodeficiency virus type 1 Anus, uterine cervix, eye, leukemia/lymphoma, endothelium
Human papillomavirus type 16 Oral cavity, tonsils, pharynx, anus, uterine cervix (HPV types 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59),
vagina, vulva, penis
Human T cell lymphotropic virus type 1 Leukemia/lymphoma
Kaposi sarcoma herpes virus Leukemia/lymphoma, endothelium
Opisthorchis viverrini Biliary tract
Schistosoma haematobium Urinary bladder
Medicines
Azathioprine Skin (nonmelanoma)
Busulfan Leukemia/lymphoma
Cyclophosphamide Urinary bladder, leukemia/lymphoma
Cyclosporine Leukemia/lymphoma, skin (nonmelanoma), multiple sites (unspecified)
Diethylstilbestrol (in utero) Uterine cervix, vagina
Estrogen/Estrogen progesterone
menopausal therapy
Corpus uteri (endometrium), ovary
Estrogen-progestogen contraceptives Liver (hepatocellular carcinoma)
Etoposide with cisplatin and bleomycin Leukemia/lymphoma
Phenacetin and analgesic mixtures
containing phenacetin
Renal pelvis and ureter
Tamoxifen Corpus uteri (endometrium)
Treosulfan Leukemia/lymphoma
Source: International Agency for Research on Cancer. IARC Monographs on Human Carcinogens and Handbooks on Cancer Prevention (https://handbooks.
iarc.fr/docs/OrganSitePoster.pdf).
4
Epidemiological science and cancer control
Toporcov TN and Wu¨nsch Filho V
CLINICS 2018;73(suppl 1):e627s
high human development index (HDI), while infection-
related cancers predominate in countries with a lower HDI
(33). Individuals in lower educational strata have fewer
opportunities to obtain information on cancer self-preven-
tion. Furthermore, most people with cancer in deprived
population groups do not have opportunities for cancer
diagnosis, and a substantial proportion of cancer cases are
diagnosed in people under 50 years of age.
Epidemiological science concerns the way social structures
and institutions influence health-related outcomes, includ-
ing cancer outcomes (34). Such studies have used methodo-
logical approaches, such as multilevel analyses, that account
for the potential influence of distant disease determinants,
such as political and socioeconomic contexts, on proximal
factors, e.g., education, diet, tobacco smoking and alcohol
drinking. Other strategies, such as mixed methods approaches
including both quantitative and qualitative techniques, are
also used.
Cancer inequality studies use paradigms based on two
distinct values (35). The first paradigm, based on liberty
and opportunity, includes studies assessing goods, services
and social capital; these studies assess cohesion among
individuals via social interactions with family, friends and
colleagues via health-related measures. A recent systematic
review study, however, has shown that cancer studies present
limited evidence of a relationship between social capital
and cancer (36). The second paradigm, based on equality
and equity, involves social justice studies assessing health-
care and may be used to measure socioeconomic status;
these studies assess the impact of lower income or educa-
tion levels on health-related outcomes. Socioeconomic
status is considered a cause of causes since neither cancer
incidence nor mortality in low socioeconomic groups are
completely explained by known risk factors (37). Positive
associations between income and education have been
consistently shown at the individual level, and the incidence
and mortality of several cancers, such as head and neck
(38) and cervical cancer (39), demonstrate that cancer may
not be a democratic disease.
The YLL rates for all cancers are lowest in both the
lowest and highest sociodemographic groups and are higher
for those in the middle socioeconomic stratum. However,
people living in countries with the lowest HDI levels die
from other conditions before reaching an age at which they
can develop cancer.
Lung cancer remains the leading cause of YLL due to
cancer in most countries. The YLL rate for lung cancer
increased by almost 15% over the past decade, although
lung cancer is clearly preventable. For other types of cancer, the
geographical pattern is very diverse and possibly reflects
differences in risk factors and the capacity of health
systems to diagnose and treat the disease (11). Colorectal,
breast and pancreatic cancers are mainly responsible for
YLL in high-income countries. By contrast, stomach, liver
and esophageal cancers are the predominant causes of YLL
due to cancer in low-HDI countries (11).
Tobacco smoking. A classic example of using epide-
miology as a tool to investigate preventable factors asso-
ciated with cancer is the investigation of tobacco smoke
carcinogenicity. The incidence of lung cancer did not become
relevant until the 18th century. By the end of the 19th century,
mostly in the beginning of the 20th century, deaths due to
lung cancer increased in Germany, the UK and the US.
In 1898, Herman Rothmann, a medical student, argued that
tobacco dust was associated with the increasing incidence of
lung cancer. In 1912, in the first monograph on lung cancer,
Isaac Adler reported tobacco and alcohol consumption as
possible causes of the disease (40). In the 1920s, factors hypo-
thesized to cause the increased lung cancer incidence rates
included tobacco smoking and other factors such as pollu-
tion, exposure to poisonous gas in World War I and the
1918-1919 global influenza pandemic. Case-control studies
performed in Germany, the UK and the US from the 1930s to
1950s (41-44) reported that lung cancer patients smoked
more often than did the controls.
In 1952, Doll and Hill assembled a cohort of 40,701 UK
doctors and assessed their tobacco smoking history via a
questionnaire (45); the participants were followed for 50 years.
Since the first results were obtained from this cohort (46,47),
tobacco smoking has been consistently recognized as a
major cause of lung cancer. In 1986, the IARC recognized
tobacco smoke as a carcinogen. According to the IARC
100E monograph, the last full revision of tobacco smoking
and cancer, evidence for associations of tobacco smoking
with cancer at 20 anatomical sites is available (29,48).
Currently, two-thirds of the world
́
s population is pro-
tected by evidence-based measures proposed by the WHO
to contain the tobacco smoking epidemic (49). Brazil is
recognized by the WHO for its successful policy against
tobacco smoking that has been implemented for the past
two decades; other countries worldwide that reported
tobacco smoking decreases were also recognized (49).
Some studies have shown the proportion of cancer cases
and deaths preventable only by eliminating tobacco smoking.
Approximately 23% of the cancer deaths and 13% of the
cancer cases in Australia in 2013 were attributable to
smoking (50), while 19% of the cancer cases in the UK in
2010 (23) as well as 30% of the incidence and 35% of the
deaths in Japan in 2005 were attributed to smoking (51).
In Brazil, 14% of cases in men and 7% of cases in women
are predicted to be attributed to smoking by 2020 (24).
These proportions need to be substantially reduced via
tobacco smoking surveillance.
Alcohol consumption, diet and physical inactivity. In
addition to tobacco smoking, alcohol consumption, unhealthy
dietary habits and physical inactivity are the major targets
for cancer prevention. Alcohol consumption is included as
a dietary habit and was estimated to be responsible for
approximately 770,000 cancer cases and 480,000 cancer
deaths worldwide in 2012 (52). From 2002 to 2012, the
proportion of cancers attributable to alcohol intake increased
from 3.5% to 5.5%, with higher values for men (7.2%) than
for women (3.5%) (52). Studies on alcohol intake as a risk
factor for cancer traditionally assessed the type and ethanol
content of the alcoholic beverages consumed as well as the
duration and frequency of consumption.
Currently, alcohol consumption is recognized to cause
cancer of the oral cavity, pharynx, larynx, esophagus,
colorectum, liver (hepatocellular carcinoma) and breast
(in females) (29). Important differences in cancer risks
according to the type of alcoholic beverage consumed are
not well supported; all alcoholic beverages contain ethanol,
which is considered carcinogenic for humans and is metabolized
into acetaldehyde (53), which is also a recognized carcinogen.
Studies on gene-environment interactions (GxEs) consis-
tently found a higher risk of alcohol-related cancers among
5
CLINICS 2018;73(suppl 1):e627s Epidemiological science and cancer control
Toporcov TN and Wu¨nsch Filho V
individuals with deficiencies in the oxidation of acetalde-
hyde to acetate (29). In addition, a recent study on alcohol
intake patterns found associations between both binge (heavy
episodic) and moderate drinking and breast cancer risk
(54). Although moderate alcohol intake might be protective
against some other chronic diseases, any alcohol intake might
increase the risk of cancer.
Studying the implications of diet on cancer is challen-
ging considering the high possibility of error in measuring
exposure. There are substantial differences in the produc-
tion and preparation of foods in distinct cultures, and dietary
patterns are highly heterogenic worldwide. A panel of
experts who reviewed the scientific literature on diet and
cancer estimated that 30% of all cancer cases are related
to diet (55). Observational studies have investigated the
influence of food items and groups as well as that of
specific nutrients on cancer risks. However, the results
from randomized clinical trials did not consistently repro-
duce the benefits seen in observational studies (56). Studies
assessing the role of dietary patterns instead of individual
foods have shown that the combined intake of certain
foods might be related to cancer risk. However, comparing
these results may be difficult when a priori indexing based
on dietary recommendations is not performed because of
the large variation in dietary patterns across cultures. High
consumption of processed meat is recognized as a risk
factor for colorectal cancer (57) and has been associated
with other cancers, such as breast, esophageal, and gastric
cancer and non-Hodgkin’s lymphoma (58). Limited evi-
dence for the protective effects of higher fruit intake and
nonstarchy vegetables against head and neck cancer (59)
and digestive tract cancer is available (60,61). Additionally,
the Mediterranean diet has been associated with a lower
risk of digestive tract cancers (62). However, more studies
assessing dietary and biological markers are needed to
elucidate the biological mechanisms involved.
Physical inactivity has been investigated as a cancer
risk factor since the 1940s (56). Currently, data on physical
activity, which is defined as recreational, commuter,
occupational and household activity, are usually collected
by self-reports of time spent on a list of activities and are
analyzed in separate or joint categories. A recent systema-
tic review of the literature on cancer at 22 body sites, which
included 541 studies, found a consistent association between
physical activity and decreased incidence and mortality
rates of both colon and breast cancer (63).
Recognition of the role of lifestyle factors in cancer may
guide interventions to reduce cancer burden. Physical
inactivity and unhealthy dietary habits are related to the
presence of excess body fat, considered a body mass index
(BMI) equal to or greater than 25. In studies using epi-
demiological designs, interventions to control excess body
fat showed sufficient evidence for cancer-preventive out-
comes in several cancers (64). Considering the recent
worldwide obesity epidemic, preventing cancer and other
chronic diseases by controlling body fat is an urgent public
health need.
Occupational exposures. Occupational cancer epide-
miology is notable, as it illustrates not only how epidemio-
logical studies can contribute to the identification of disease
risk factors but also how searching for occupational causes of
diseases leads to both methodological advances in epi-
demiological study designs and a better understanding of
carcinogenesis. Knowledge about occupational carcinogens
is used to establish regulations on exposure limits or agent
bans, thus reducing the cancer burden.
While Bernardino Ramazzini had insights into occupa-
tional cancer in his De Morbis Artificum Diatriba of 1700,
the first consistent evidence of occupational causality in
cancer was reported in 1775 by Percival Pott, who noted
the occurrence of scrotum cancer among patients who had
worked as chimney sweeps at a young age (65). Based on
this observation, Pott concluded that their occupation as
children or adolescents exposed them to soot, a factor related
to the scrotal neoplasia. One hundred and forty years after
Pott’s original epidemiological description, an experimental
model of soot carcinogenesis was reported in 1915 by
Yamagiwa and Ichikawa, who described the induction of
skin tumors in animals by tar. In the early 1930s, various
polycyclic aromatic hydrocarbons were isolated from active
coal tar fractions. Finally, in the 1940s, benzopyrene was
isolated and identified as the carcinogen responsible for the
tumors described by Pott (65-68).
Pott was not only the first to suggest occupational causes
of cancer but also the first to introduce the concept of latency,
which is defined as the time interval between exposure and
disease manifestation or diagnosis and is both a very lengthy
period during cancer development and a key concept in the
carcinogenesis process. Thus, latency should always be
considered in cancer exposure analyses (69).
During the 20th century, numerous carcinogenic agents
present in the workplace, including arsenic, asbestos, benzene,
cadmium, chromium, nickel, and vinyl chloride, were identi-
fied. Noteworthy examples are briefly described.
Problems commonly seen in occupational epidemiol-
ogy are related to the quality of the exposure assessment.
Epidemiologists must pay particular attention to avoiding
information bias and confounding, which lead to the
underestimation of risks (70). Understanding the causality
of diseases is a gradual process that requires specific alter-
natives using distinct epidemiological study designs. The
evolutionary realization of the effects of inhaling asbestos
fibers on human health is illustrative of this concept.
Although the consequences of inhaling asbestos dust on
health have been observed since antiquity, in 1907, Murray
was the first to describe asbestosis, the disease responsible
for the death of a worker exposed to asbestos fibers during
textile spinning (71). In 1935, the pathologist Gloyne noted
the carcinogenic potential of asbestos fibers by describ-
ing the occurrence of two squamous cell lung carcinoma
cases in women with asbestosis (72). This finding was also
confirmed by Lynch and Smith (73), who reported a case of
lung cancer in a textile worker and included a detailed
description of the patient’s occupational history. Mere-
wether (74) and Gloyne (72) reported that 13.2 and 14.1%
of lung tumors, respectively, were due to asbestosis, as
determined by necropsy.
In 1955, the epidemiologist Richard Doll definitively
established an association between occupational exposure
to asbestos fibers and lung cancer via a retrospective cohort
study on mortality (75). Despite the strength of Doll’s
study, criticism emerged because of the lack of data on
smoking; this issue was resolved by Selikoff et al. (76).
Simultaneously, evidence of an association between asbestos
exposure and pleural mesothelioma emerged in case series
studies (77,78). Later, the synergistic effect of smoking and
asbestos exposure on lung cancer was identified (79-82).
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From the 1950s to the 1970s, asbestos use was wide-
spread worldwide. Since the 1980s, 55 countries world-
wide have banned asbestos because of epidemiological
and laboratory evidence of its hazards; Brazil was the
most recent country to ban the extraction, industrialization
and commercialization of asbestos throughout its terri-
tory based on a Federal Supreme Court decision made in
November, 2017. Unfortunately, the benefits from this ban
require more time to be realized, as mesothelioma rates are
still high and continue to increase in many European
countries given the long latency period between exposure
and disease occurrence (11). Increasing trends in mesothe-
lioma mortality have been observed in Brazil, and deaths
by mesothelioma are expected to increase and peak in the
next decade, approximately one decade after the peak in
developed countries (83).
Epidemiological evidence of relationships between organic
solvents and cancer has also been important for the control
of such occupational carcinogen exposures. An estimated
one million people were exposed to solvents in the US in
the 1980s, and in the Canadian city of Montreal, 40% of
male cancer patients were exposed to solvents (84).
Benzene, commonly used as a solvent, is among the
20 most widely used chemicals worldwide and is identi-
fied by the WHO as one of ten chemicals of major public
health concern (85). Benzene is a colorless and highly
flammable liquid with a sweet smell; this aromatic hydro-
carbon is a natural constituent of crude oil and a com-
ponent of gasoline that has also been identified in industrial
emissions and tobacco smoke.
In the past century, the effects of benzene on human
carcinogenesis have been evidenced in case-control and cohort
studies. Based on results from case-control studies showing a
strong relationship between occupational benzene exposure
and leukemia, the IARC classified benzene as a human
carcinogen in 1982 (86). Several subsequent studies have
confirmed benzene as a powerful carcinogen. In the last
full revision conducted by the IARC, substantial evidence
supporting the carcinogenicity of benzene to humans was
reiterated, as this chemical was associated with both acute
myeloid leukemia and acute nonlymphocytic leukemia.
Additionally, positive associations between benzene expo-
sure and acute lymphocytic leukemia, chronic lymphocytic
leukemia, multiple myeloma, and non-Hodgkin’s lymphoma
have been observed (29). Noteworthy results on benzene
carcinogenicity emerged from two large cohort studies;
the first comprised 1,212 white men employed between
1936 and 1975 to produce Pliofilm, a process requiring
large volumes of benzene as a solvent, (87) and the second
cohort comprised 74,828 workers recruited from 672 facto-
ries in China (88).
Many human carcinogens are occupational carcinogens.
Considering evaluations published in IARC monographs,
Siemiatycki et al. augmented our knowledge of occupa-
tional carcinogens (89) by reporting 28 agents used in
several occupations as definite carcinogens, 27 as probable
occupational carcinogens, and 113 as possible occupational
carcinogens. Therefore, substantial work on occupational
carcinogen surveillance and effective interventions must be
performed to prevent workplace exposure to these agents.
Infectious agents. Studies establishing links between
infectious agents and cancer have laid a foundation for
prevention. For example, Helicobacter pylori (H. pylori) is
associated with gastric cancer. Based on results from case-
control and cohort studies showing that patients with tumors
exhibited high proportions of IgG antibodies against
H. pylori, in 1994, the IARC classified H. pylori as a carcinogen
related to gastric cancer and gastric lymphoma (90). Rapid
advances in molecular biology have allowed microbiome
approaches to be used in epidemiological studies, and the
association between H. pylori infection and gastric cancer
has consistently remained. However, recent studies have
demonstrated that H. pylori infection might be protective
against esophageal cancer, increasing the difficulty of pre-
venting cancer by controlling bacteria at the population
level (91). Results from meta-analyses have suggested that
the eradication of H. pylori might prevent gastric cancer and
that this approach is most likely more successful in healthy
individuals than in those with noncancer gastric diseases or
symptoms, although the authors noted that more studies
are needed to confirm this conclusion (92,93).
The proportion of infection-related cancer cases is higher
in low- and middle- income countries, and prevention by
vaccination has been seriously considered. Universal hepa-
titis B vaccinations began in Taiwan in 1984. Studies includ-
ing data from Taiwan’s National Cancer Registry showed
decreased incidences of hepatocellular carcinoma in children
after vaccination began (94).
Another successful story in the search for infectious
agents related to cancer is the discovery of connections
between human papillomavirus (HPV) infection and uterine
cervical neoplasms. In the 1980s, zur Hausen isolated and
characterized HPV 16 and HPV 18 in uterine cervical biopsies.
Since then, studies have been conducted to clarify the
causal role of HPV in cervical cancer (95). In a study using
PCR to evaluate HPV DNA in 1,000 frozen cervical cancer
biopsy samples from America, Africa, Europe and Asia,
HPV DNA was detected in 93% of the specimens, and the
negative samples showed positive results when reana-
lyzed with the L1 and L7 primers (96). The association
between HPV and cervical cancer is highly dependent on
the sensitivity of the laboratory technique used for HPV
detection. Thus, advances in molecular biology have increased
the validity of the results, which have indeed shown that HPV
causes cervical cancer (97).
The association between HPV and other types of cancer,
such as anal and oropharyngeal neoplasms, has been investi-
gated, and different causal natures have been shown. Not
all oropharyngeal cancers are HPV-related, but HPV infec-
tion appears to modify both the disease profile and prognosis
(98,99), thus highlighting HPV infection as a disease-modifying
entity.
Worldwide, 4.5% of cancers are attributable to HPV infec-
tion; the proportion is highest for cervical cancer (83%). The
proportion of cancer attributable to HPV infection in women
ranges from o3% in Australia, New Zealand and the US to
420% in India and sub-Saharan Africa. In Latin America, this
proportion is 13% (100).
In 2012, approximately 15% of all cancer cases worldwide
were attributable to infectious agents, and two-thirds of
these cancers occurred in less-developed countries. The four
infectious agents contributing to most cancers (92%) were
H. pylori, HPV, hepatitis B virus (HBV) and hepatitis C virus
(HCV). Other cancer-related infectious agents include human
immunodeficiency virus type 1 (HIV-1), Epstein-Barr virus
(EBV), human herpesvirus type 8 (HHV-8), human T cell
lymphotropic virus type 1 (HTLV-1), Opisthorchis viverrini,
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Clonorchis sinensis, and Schistosoma haematobium. Remarkably,
in both less- and more-developed countries, infection-attributable
cancer incidences are higher in people aged 50 years or
younger (22). Undoubtedly, studies on infection and cancer
will continue to increase; several other infectious agents
have been associated with different types of cancer, but the
contributions of these agents to carcinogenesis are not yet
completely understood.
Molecular biology and genetics. Studies comparing
cancer rates in migrants and natives have attempted to
elucidate the influences of endogenous risk factors on cancer.
Additionally, epidemiological studies assessing cancer in
families or comparing cancer risk in twins have attempted to
disentangle the association of inherited characteristics with
cancer; however, these studies have not completely explained
how cancer is attributable to genetics or lifestyle. However,
genetic variants are unlikely to account for most cancer
cases. Only 5 to 10% of cancer cases are attributable to
high-penetrance mutations, such as those in BRCA1 or
mismatch repair genes (37).
Currently, advances in genomics and other -omics
technologies have allowed the character of genomic and
epigenomic variations in humans and pathogens, as well
as the relationships of these variations with environmental
factors, to be assessed in the setting of carcinogenesis.
Epidemiology plays a role in assessing the validity of these
technologies when applied to a population (101). Current
cancer etiology studies may include measurements of
genomic, proteomic, metabolomic, epigenomic, mitochon-
drial DNA-related, and microbiome-related parameters to
better understand disease complexity (101).
GxE assessments are an interesting approach for study-
ing cancer etiology. However, to date, the relationship between
GxEs and cancer causality has been poorly established. An
example of this relationship, however, is the possible positive
association between alcohol intake and genetic polymorphisms
in alcohol metabolism-related genes and the risk of head and
neck cancers and digestive tract cancers (102-104). Obstacles to
the assessment of GxEs are related to the necessity of high-
quality longitudinal exposure data and large sample sizes so
that a wide range of exposure levels can be studied to obtain
statistical power (105).
Another possible avenue for exploring the connections
between low-penetrant gene variants and external risk
factors is Mendelian randomization, which uses genetic
variability as an instrumental variable proxy for the effect
of modifiable exposures (106,107). Considering that gene
variability distributions are not influenced by environ-
mental exposures in the population, gene variability might
be a nonbiased or unconfounded proxy for exposure, thus
mimicking a randomized trial and serving as an opportu-
nity to test hypotheses generated in observational studies.
Consistent results have been obtained for known risk
factors for specific cancers. For example, in studies using
this approach, acetaldehyde-metabolizing genes have been
linked to head and neck cancer (108), and genetic scores
for higher adult BMIs were correlated with increased risks
of colorectal, ovarian and lung cancer (109). However, this
approach has some limitations, such as the lack of suitable
polymorphisms for studying exposures of interest, the
failure to establish a reliable genotype-outcome association
and the presence of confounding genotype-phenotype disease
associations (106).
’ EVALUATION OF EARLY CANCER DETECTION
METHODS
Screening is a powerful strategy to control some cancers,
such as cervical cancer. Herein, we do not aim to review epi-
demiological evidence or deliver a polemic regarding cancer
screening policies; instead, we aim to describe the purpose of
epidemiology in investigating the impacts of early diagnosis
on cancer control programs.
Disease screening was first conceptualized in 1861 by
Horace Dobell, who proposed routine and periodic medical
examinations and laboratory tests to discover physiological
defects in their earliest state (110). In the 20th century, an
emerging belief in the medical community established that
a disease course could be altered if an early diagnosis was
made (111). In 1907, Charles Childe hypothesized that although
cancer is not incurable, delays in diagnosis would make it so,
thus proposing that most cancers are curable if diagnosed
early. From the 1930s to the 1950s, medical associations began
recommending screening based more on intuition than on
scientific evidence (111).
In 1968, Wilson and Jugner proposed essential systematic
procedural requirements for which diseases and individuals
to select for screening programs (112). Forty years later,
Andermann et al. (113) published a synthesis of the emerging
screening criteria proposed during this period, one of the
main principles of which was that the disease needed to be
considered an important health problem in the population in
order to be eligible for screening.
An adequate study design with proper methods and analysis
procedures is key to studying the effectiveness of screening
for specific cancers (114), and the challenges of improving the
design of screening studies have improved epidemiological
methods. Comparing mortality instead of survival between
screened and unscreened individuals can prevent lead-
time bias, which refers to a finding of increased survival
only because of diagnosis anticipation. Another challenge in
the design and interpretation of screening studies is that the
survival rates of screened patients could be better than the
survival rates of patients not screened solely because of their
less-aggressive disease, which would explain why cancers
are found at an early stage.
To assess the results of screening programs, potential harm-
ful effects should be assessed and balanced against potential
benefits. Thus, if early diagnosis does not affect the disease
course, early awareness of the disease only makes the indi-
vidual feel sick for longer. Thus, the harmful impacts of
screening should be important considerations for epide-
miologists and public health professionals (115).
Cancer screening recommendations have been made by
preventive task forces in countries such as Australia, Canada
and the US, or by councils such as the Council of the
European Union, which suggests evidence supporting cur-
rent screening for uterine cervical, breast, and colorectal
cancers (116-118).
Current and future challenges in cancer epidemiology
To date, epidemiology has made valuable contributions to
cancer prevention and control, some of which have been
outlined herein. The risk assessment mission of epidemiol-
ogy is controversial, but this mission is essential to better
understand disease mechanisms; furthermore, it informs
control policies. New research pathways, such as the inclu-
sion of big data related to genetics, are required to advance
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the risk assessment theory in cancer. Genetic epidemiology
evaluates the causal mechanisms of cancer while simulta-
neously considering genes and environmental factors, and
Mendelian randomization has emerged as a plausible method
for studying the interaction among these factors (106).
Consistent analysis of the combined effects of genes and
environmental components in cancer studies with large
sample sizes is necessary, and establishing international
consortia is an approach for overcoming this challenge.
The surveillance of cancer incidence and mortality rates in
a population provides awareness for clearly defining policy
decision priorities in order to reduce cancer risks. Addition-
ally, these programs must be continuously monitored so
that barriers arising from emergent local circumstances can
be detected. Thus, many more implementation studies are
necessary before these programs can effectively control cancer.
These activities are within the scope of epidemiology, the
basic science of public health. However, while such applica-
tions are not discussed herein, epidemiology also has broad
clinical applications in the study of cancer prognosis. Thus,
successful cooperation among epidemiologists, clinicians
and laboratory scientists is imperative to better understand
cancer etiology, and consequently, cancer control. Primary
prevention is the most effective approach for controlling
cancer, but preventive initiatives must also be integrated
with early diagnosis and proper therapies (37). Furthermore,
epidemiologists should collaborate with public health staff
and population stakeholders to implement successful cancer
prevention and control programs.
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